1. Evans DB, Abbruzzese JL, Willett CG: Cancer of the pancreas. Cancer: Principles and Practice of Oncology. Edited by: De Vita VT Jr, Hellman S, Rosenberg SA. 2001, Philadelphia, PA, Lippincott Williams and Wilkins, 1126-1161. 6
2. Rosewicz S, Wiedenmann B: Pancreatic carcinoma. Lancet. 1997, 349 (9050): 485-489. 10.1016/S0140-6736(96)05523-7.
3. Louvet C, Labianca R, Hammel P, Lledo G, Zampino MG, André T, Zaniboni A, Ducreux M, Aitini E, Taieb J, Faroux R, Lepere C, de Gramont A: Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol. 2005, 23 (15): 3509-3516. 10.1200/JCO.2005.06.023.
4. Poplin E, Levy DE, Berlin J, Rothenberg M, Cella D, Mitchell E, Alberts S, Benson A: Phase III trial of gemcitabine (30-minute infusion) versus gemcitabine (fixed-dose rate-infusion [FDR]) versus gemcitabine+oxaliplatin (GEMOX) in patients with advanced pancreatic cancer (E6201). J Clin Oncol. 2006, 24 (18S): abstract LBA4004.
5. Heinemann V, Quietzsch D, Gieseler F, Gonnermann M, Schoenekaes H, Rost A, Neuhaus H, Haag C, Clemens M, Heinrich B, Vehling-Kaiser U, Fuchs M, Fleckenstein D, Gesierich W, Uthgenannt D, Einsele H, Holstege A, Hinke A, Schalhorn A, Wilkowski R: Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol. 2006, 24 (24): 3946-3952. 10.1200/JCO.2005.05.1490.